Rates of Dermoscopy Use for Melanoma Diagnosis in the Miami VA Medical Center
In the past 25 years, dermoscopy has had a major impact on the diagnosis of cutaneous lesions. Adequate dermoscopy training can be cost-effective and reduce melanomaassociated morbidity and mortality. 1 Since 2006, dermatoscopes have been provided to incoming dermatology residents at the University of Miami as a part of the training curriculum in addition to didactic dermoscopy training by a pigmented lesion expert. Figure) . There was an inverse correlation between dermoscopy use and Breslow depth with significantly thinner melanomas associated with dermoscopy-use cases compared to nondermoscopy use cases (median Breslow depth 0 mm vs 0.26 mm; Wilcoxon rank-sum test, P < .001).
Discussion | Similar to the trend seen at our training institution, the rates of dermoscopy use have increased over the past 2 decades. In a 2002 survey, 2 only 38% of US dermatology residents reported dermoscopy training during their residency, and more than one-third had never used a dermatoscope. The same group updated their survey in 2010 and noted a 40% increase in the proportion of residency programs that used dermoscopy and 52% increase in those residents receiving training. 3 This same temporal trend has been reported in the United Kingdom: 54% of respondents reported regular dermoscopy use in 2003, compared with 98.5% in 2012. In the United States, dermoscopy users are more likely to be younger, The increasing rates of dermoscopy use demonstrate a significant trend over time (P < .001).
Letters recently graduated, and involved with teaching residents. 4 The reported reasons for dermoscopy nonuse are consistently due to lack of dedicated training. Our study examines the use of dermoscopy (whereby clinical documentation is a marker for use) for melanoma diagnosis at the Miami VA Medical Center and suggests that dermoscopy learners have a positive impact on the secondary prevention of melanoma, by way of identifying thinner lesions at diagnosis. Our findings also illustrate the actual rates of dermoscopy use among physicians-in-training in a longitudinal fashion. Physicians-in-training under the supervision of an attending physician are the key health care providers performing skin cancer screenings of patients in the VA system. The present strengths of our study include consistent record keeping by electronic medical record, reliable pathologic thresholds, and relative uniformity of thresholds for biopsy.
This study has some limitations that have to be acknowledged. Average Breslow depth has been skewed toward thinner tumors over time due to multifactorial factors including increased biopsy rates, improved early detection, and changes in histopathologic measures for borderline lesions. 5 Second,
we only included those cases with verified documentation of dermoscopy use, so the actual rates of use may be higher. Finally, the homogenous demographics of the VA study population who have equalized access to care may limit the generalizability of this study.
It is known that dermoscopy use improves the malignantto-benign ratio for melanocytic lesions in dermoscopy users compared with nonusers. 6 We advocate for providing devices to residents along with structured dermoscopy education to encourage postresidency use. 
OBSERVATION

Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid
Immune checkpoint inhibitors have dramatically improved patient outcomes across a variety of cancers. Recently, reports of bullous skin eruptions clinically consistent with bullous pemphigoid (BP) secondary to programmed cell death 1 (PD-1) inhibition have emerged. 1 We report a case of nivolumabinduced BP with complete response to rituximab therapy.
Report of a Case | A man in his 80s with metastatic adenocarcinoma of the lung began treatment with nivolumab, 3 mg/kg every 2 weeks. One year into therapy (26 cycles), he developed pruritus and urticarial lesions immediately after an infusion that resolved after treatment with methylprednisolone. He was subsequently treated with methylprednisolone before each nivolumab infusion, but his symptoms continued to worsen. After 40 nivolumab cycles, he underwent a dermatologic evaluation and was found to have tense vesicles and bullae on erythematous bases covering 4% to 5% of his body surface area ( Figure 1A and B) . He also had a solitary gingival bulla ( Figure 1C) . Pathologic analysis showed a subepidermal vesicle with numerous eosinophils (Figure 2) . Direct immunofluorescence findings were strongly positive, showing linear staining for C3 and IgG at the dermoepidermal junction. Indirect immunofluorescence (IIF) findings were positive for IgG against the basement membrane zone. Serum enzymelinked immunosorbent assay (ELISA) results were positive for antibodies to bullous pemphigoid antigen 2 (BP180) and desmoglein 3 (Dsg3). The patient was diagnosed with BP, and based on the timing and flares with infusions, the BP was believed to be triggered by PD-1 inhibition. Notably, by the time of this diagnosis, he had achieved complete remission of his metastatic disease.
Owing to the progressive bullae, nivolumab treatment was discontinued, and the patient was treated with multiple oral steroid courses that were complicated by flares when taper was attempted, severe delirium requiring hospital admission, and 2 vertebral osteopenic compression fractures. In collabora-
